Analyst Price Target is $6.00
▲ +270.37% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for BioLineRx in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 270.37% upside from the last price of $1.62.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in BioLineRx.
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.